The antimalarial drug Pyronaridine was developed in the 1970s and '80s in response to the rise in chloroquine-resistant Plasmodium. In addition to effectively treating malaria, it showed significantly lower toxicity compared to chloroquine, 1b,2 and when administered in combination with other antimalarials such as sulfadoxine and pyrimethamine, little-to-no resistance to the drug was observed. Current research into repurposing pyronaridine for treatment of nonmalarial parasitic diseases, 4 cancer, and bacterial and viral 7 infections has shown promise, including its potential in the ongoing fight against the SARS-CoV-2 virus responsible for the COVID-19 pandemic. 7b Nonetheless, its primary purpose remains as a treatment for malaria, especially in tropical regions of the world. However, from the perspective of pharmaceutical companies, justifying the sale of drugs to the developing world can be fiscally challenging; hence, the development of a synthetic route which minimizes cost is imperative to incentivize production of Pyronaridine. Moreover, increasing pressure from governmental restrictions, such as the REACH regulation in the EU, requires chemical manufacturers to reduce their environmental footprint, providing additional incentive for development of a greener route to pyronaridine.